2026年2月6日，恒生科技指数早盘低开震荡，盘中一度跌超1.5%，随后跌幅收窄。截至14时38 分，恒生科技指数报5349.48点，较前一交易日收盘下跌约0.34%。 恒生科技ETF南方（520570）当日盘中跟随指数震荡下行，盘中成交活跃，成交金额约1.15亿元， 换手率约4.41%，盘中振幅较大，显示多空博弈较为激烈。 资金面上，该ETF昨日获净申购约7785万元，在跨境ETF中净流入排名第17/212，近5日累计净流入 约7875万元，资金呈现"越跌越买"特征，显示中长期资金对港股科技板块的配置意愿较强。 消息面上，券商普遍认为港股科技板块当前估值处于近五年低位，恒生科技指数与创业板指收益差 处于历史高位，安全边际较高；同时，港股科技板块在AI应用端和商业化环节占据核心位置，盈利增 长确定性较强，叠加海外弱美元和人民币企稳预期，南向资金与外资回流有望共同支撑板块估值修复。 南向资金方面，2月4日港股通净买入约61.6亿港元，其中腾讯控股、阿里巴巴等科技龙头获大额净 买入；2月5日盘中南向资金净买入已超80亿港元，显示内地资金对港股科技资产的配置意愿持续升温。 恒生科技ETF南方（520570）紧密跟踪 ...

Group 1 - The core viewpoint of the news highlights the strong performance of the Hang Seng Biotechnology ETF (159615), which surged over 4% and is experiencing active trading, with a turnover of 48.91 million yuan and a turnover rate of 14.78% [1] - The Hang Seng Biotechnology Index increased by 3.14%, with significant gains in constituent stocks such as 3SBio, which rose by 29.93%, and other companies like Rongchang Bio and Innovent Biologics also showing positive movements [1] - 3SBio announced a licensing agreement with Pfizer for the PD-1/VEGF bispecific antibody SSGJ-707, which includes an upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion, along with a double-digit percentage royalty on net sales in licensed regions [1] Group 2 - Guojin Securities emphasizes that the innovative drug sector within the pharmaceutical industry is the most noteworthy area for investment, with a focus on capturing opportunities throughout 2025 [2] - The report indicates that leading innovative drug companies are expected to see continued commercial sales and business development performance, particularly in oncology, autoimmune diseases, and chronic conditions, which will support growth and valuation recovery for leading companies in these segments [2] - The news mentions related investment products, including the Hang Seng Biotechnology ETF (159615) and other ETFs, which aim to help investors seize opportunities in the Hong Kong stock market [2]